Report of Foreign Issuer (6-k)
August 08 2018 - 5:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of:
August 2018 (Report
No. 1)
Commission file number:
001- 38041
THERAPIX BIOSCIENCES LTD.
(Translation of registrant’s name
into English)
4 Ariel Sharon Street
HaShahar Tower, 16th Floor
Givatayim 5320047, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
☒
Form
40-F
☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
On July 31, 2018, Therapix Biosciences
Ltd. (the “Company”) entered into an Agreement for Convertible Equity (the “Convertible Equity Agreement”)
with Therapix Healthcare Resources, Inc. (“THR”), which is a company incorporated in Delaware and an unaffiliated third
party. Under the Convertible Equity Agreement, the Company loaned an aggregate of $1,300,000 (the “Loan”) to THR. The
maturity date of the Loan, which accrues interest at a rate of nine percent (9%) per annum, will be upon demand of the Company
at any time after August 1, 2018, the closing date (the “Maturity Date”). At the election of the Company, the entire
Loan shall be converted into that number of shares of the most senior class of shares of THR existing at the time of such conversion,
at a price per share equal to the fair market value of such shares as shall be determined by THR’s Board of Directors, it
being acknowledged that, following the exercise of such conversion right, the Company shall hold 20.96% of THR. In addition, the
Company shall have the right to appoint 50% of the members of the THR Board of Directors.
The proceeds of the Loan were used by THR
to acquire eight pain clinics, seven of which are located in Tennessee and one in Arkansas, as well as a fully equipped laboratory
in Tennessee from Anesthesia Services Associates PLLC. (d/b/a Comprehensive Pain Specialist) on August 1, 2018.
The information contained in this Report
is hereby incorporated by reference into the Company’s Registration Statement on Form F-3, File No. 333-225745 and Registration
Statement on Form S-8, File No. 333-217765.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Therapix Biosciences Ltd.
(Registrant)
|
|
|
|
Date: August 7, 2018
|
By
|
/s/ Ascher Shmulewitz
|
|
Name:
|
Ascher Shmulewitz, M.D, Ph.D.
|
|
Title:
|
Chief Executive Officer
|
2
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2024 to May 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From May 2023 to May 2024